Meanwhile, MUC-1 has been implemented in a variety of preclinical ACC studies and demonstrated repeatedly a different response pattern and clinically frequently observed drug resistance phenotype compared to NCI-H295R [20,21,22,23,24,25,26,27,28,29]. The gene discussed is MUC1; the disease is adrenal cortex carcinoma.